Recurrent Fallopian Tube Cancer (DBCOND0034507)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Niraparib	A poly-ADP ribose polymerase inhibitor used to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer responding to platinum based chemotherapy.	Poly [ADP-ribose] polymerase 1target Poly [ADP-ribose] polymerase 2target Carboxylesteraseenzyme Cytochrome P450 1A2enzyme Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter ATP-dependent translocase ABCB1transporter Albumincarrier
Olaparib	A poly (ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.	Poly [ADP-ribose] polymerase 1target Cytochrome P450 3A4enzyme Cytochrome P450 2B6enzyme Poly [ADP-ribose] polymerase 2target Protein mono-ADP-ribosyltransferase PARP3target Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Aldo-keto reductase family 1 member C3target UDP-glucuronosyltransferase 1A1enzyme Albumincarrier Alpha-1-acid glycoprotein 1carrier
Rucaparib	A poly (ADP-ribose) polymerase (PARP) inhibitor used to treat recurrent ovarian and prostate cancers in previously treated adults.	Poly [ADP-ribose] polymerase 1target Poly [ADP-ribose] polymerase 2target Protein mono-ADP-ribosyltransferase PARP3target Cytochrome P450 2D6enzyme Cytochrome P450 1A2enzyme Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter Solute carrier family 22 member 1transporter ATP-binding cassette sub-family C member 4transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 6transporter Organic anion transporter 3transporter Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Cytochrome P450 3A43enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C8enzyme UDP-glucuronosyltransferase 1A1enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01982487	Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission	Epacadostat vCP2292	treatment	1 / 2	withdrawn
NCT05126342	Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi	Dostarlimab Niraparib	treatment	2	not_yet_recruiting
NCT01673217	Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer	2'-Deoxycytidine Cancer/testis antigen 1 Decitabine Doxorubicin Incomplete Freund's adjuvant NY-ESO-1 peptide vaccine Sargramostim	treatment	1	completed
NCT01962948	Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Ganetespib Paclitaxel	treatment	1 / 2	terminated
NCT01652794	Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer	Carboplatin Gemcitabine	treatment	1	completed
NCT01764789	Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer	No drug interventions	supportive_care	Not Available	completed
NCT02785250	Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer	Cyclophosphamide Epacadostat	treatment	1 / 2	active_not_recruiting
NCT01536054	Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Sargramostim Sirolimus vCP2292	treatment	1	completed
NCT01747798	Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Auranofin	treatment	0	completed
NCT01200797	SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin	SJG-136	treatment	2	terminated
NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	Niraparib Oregovomab	treatment	2	active_not_recruiting
NCT02050009	Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Carboplatin Metformin Paclitaxel	treatment	1	withdrawn
NCT02122185	Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Metformin	treatment	2	active_not_recruiting
NCT00388037	Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	Sunitinib	treatment	2	completed
NCT01853644	Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Tivozanib Tyrosine	treatment	2	completed
NCT03564340	Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers	Cemiplimab Sarilumab Ubamatamab	treatment	1 / 2	recruiting
NCT00278343	Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer	Cediranib	treatment	2	completed
NCT02046421	Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	Carboplatin Gemcitabine Mifepristone	treatment	1	completed